Logo do repositório
 
Publicação

Outcomes from the International Society of Nephrology Hemolytic Uremic Syndromes International Forum

2024-12Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorKavanagh, David
dc.contributor.authorArdissino, Gianluigi
dc.contributor.authorBrocklebank, Vicky
dc.contributor.authorBouwmeester, Romy N.
dc.contributor.authorBagga, Arvind
dc.contributor.authorter Heine, Rob
dc.contributor.authorJohnson, Sally
dc.contributor.authorLicht, Christoph
dc.contributor.authorMa, Alison L.T.
dc.contributor.authorNoris, Marina
dc.contributor.authorPraga, Manuel
dc.contributor.authorRondeau, Eric
dc.contributor.authorSinha, Aditi
dc.contributor.authorSmith, Richard J.H.
dc.contributor.authorSheerin, Neil S.
dc.contributor.authorTrimarchi, H.
dc.contributor.authorWetzels, Jack F.M.
dc.contributor.authorVivarelli, Marina
dc.contributor.authorVan de Kar, Nicole C.A.J.
dc.contributor.authorGreenbaum, Larry A.
dc.contributor.authorLungu, Adrian Catalin
dc.contributor.authorŻurowska, Aleksandra
dc.contributor.authorGerogianni, Alexandra
dc.contributor.authorDurkan, Anne
dc.contributor.authorSchijvens, Anne
dc.contributor.authorLapeyraque, Anne Laure
dc.contributor.authorJava, Anuja
dc.contributor.authorAwan, Atif
dc.contributor.authorCovella, Bianca
dc.contributor.authorDixon, Brad
dc.contributor.authorEl Sissy, Carine
dc.contributor.authorDuinevel, Caroline
dc.contributor.authorMaville, Christine
dc.contributor.authorTurudic, Daniel
dc.contributor.authorKarpman, Diana
dc.contributor.authorHaffner, Dieter
dc.contributor.authorTrembecka-Dubel, Elżbieta
dc.contributor.authorOzaltin, Fatih
dc.contributor.authorEmma, Francesco
dc.contributor.authorSchaefer, Franz
dc.contributor.authorKang, Hee Gyung
dc.contributor.authorTrimarchi, Hernán
dc.contributor.authorTrujillo, Hernando
dc.contributor.authorUlasi, Ifeoma
dc.contributor.authorEkwueme, Alex
dc.contributor.authorMenne, Jan
dc.contributor.authorLaurence, Jeffrey
dc.contributor.authorCalado, Joaquim
dc.contributor.authorHofer, Johannes
dc.contributor.authorZuber, Julien
dc.contributor.institutionNOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
dc.contributor.pblNature Publishing Group
dc.date.accessioned2024-11-28T23:10:00Z
dc.date.available2024-11-28T23:10:00Z
dc.date.issued2024-12
dc.descriptionFunding Information: D.K. has received advisory board payments from Idorsia, Novartis, Chemocentryx, Alexion, Samsung, Sobi, Gyroscope Therapeutics, Purespring and Apellis. G.A. has received honoraria from Alexion Pharmaceuticals, Alnylam, Roche Novartis and Sobi for giving lectures, and for participating in advisory boards. C.L. has received honoraria as advisor or speaker from Alexion, AstraZeneca Rare Disease, Apellis Pharmaceuticals, Inc., Novartis, and Pfizer Inc. M.N. has received honoraria from Alexion Pharmaceuticals and Sobi for giving lectures, and for participating in advisory boards, and she has received research grants from Omeros, Gemini, Novartis and BioCryst Pharmaceuticals. M.P. has received honoraria from Alexion, Novartis, Otsuka, GSK, Samsung and Sanofi for lectures and advisory boards. E.R. is a member of the scientific advisory board of the Global aHUS registry launched by Alexion Pharmaceuticals. He received fees from Alexion for travels, communications, and clinical studies. R.J.H.S. directs the Molecular Otolaryngology and Renal Research Laboratories, which provides genetic and complement activity testing for the thrombotic microangiopathies. He also serves as a consultant for Novartis and receives research support from the National Institutes of Health. N.S. has received honoraria for advisory boards and talks for Alexion Pharmaceuticals, Astra Zeneca, Novartis, Roche, Therakos. Trial committee involvement for Roche and Novartis. H.T. has received honoraria from Alexion, Alpine Astra-Zeneca, Bayer, Biosidus, BioCryst, BMS, Calliditas, Chinook, Dimerix, Genzyme, Glaxo-Smith Klyne, Novartis, Omeros, Roche, Sanofi, Takeda, Retrophin-Travere, Vera Therapeutics, Visterra-Otsuka M.V. provides consultancy or participated in sponsored clinical trials by Novartis, Roche, Apellis, Alexion, Travere, PureSpring, Chinook, Chemocentrix, Biocryst, has given sponsored lectures for Vifor, Travere, Roche, Novartis, Glaxo. N.C.A.J.vdK. has received consultancy fees from Roche Pharmaceuticals, Novartis, Samsung and Alexion and is (sub) investigator in the APL2-C3G trial, Apellis and APPEAR-C3G trail, Novartis.J.W. has received grants for clinical trials; honoraria scientific advisory committee from Alexion; HiBio; Novartis. Funding Information: The authors thank Monica Moorthy, Charu Malik, Paolo Zavalloni, Th\u00E9o Treppo, Charleigh Claire, and Ilaria Pastorino for organisational support of this forum. The authors would also like to thank Giedre Peseckyte, the forum medical writer. The ISN aHUS International forum was supported by Alexion AstraZeneca Rare Disease. The authors did not receive any compensation for their work on this manuscript. Publisher Copyright: © 2024 International Society of Nephrology
dc.description.abstractHemolytic uremic syndromes (HUSs) are a heterogeneous group of conditions, only some of which are mediated by complement (complement-mediated HUS). We report the outcome of the 2023 International Society of Nephrology HUS International Forum where a global panel of experts considered the current state of the art, identified areas of uncertainty, and proposed optimal solutions. Areas of uncertainty and areas for future research included the nomenclature of HUS, novel complement testing strategies, identification of biomarkers, genetic predisposition to atypical HUS, optimal dosing and withdrawal strategies for C5 inhibitors, treatment of kidney transplant recipients, disparity of access to treatment, and the next generation of complement inhibitors in complement-mediated HUS. The current rationale for optimal patient management is described.en
dc.description.versionpublishersversion
dc.description.versionpublished
dc.format.extent13
dc.format.extent938397
dc.identifier.doi10.1016/j.kint.2024.09.012
dc.identifier.issn0085-2538
dc.identifier.otherPURE: 103607213
dc.identifier.otherPURE UUID: 82d03948-c6a0-448a-a642-1ff262bf4af0
dc.identifier.otherScopus: 85209153266
dc.identifier.otherPubMed: 39395628
dc.identifier.otherORCID: /0000-0002-1194-3392/work/172737539
dc.identifier.urihttp://hdl.handle.net/10362/175990
dc.identifier.urlhttps://www.scopus.com/pages/publications/85209153266
dc.language.isoeng
dc.peerreviewedyes
dc.subjectacute kidney injury
dc.subjectC5
dc.subjectcomplement
dc.subjecthemolytic uremic syndrome
dc.subjectthrombotic microangiopathy
dc.subjectNephrology
dc.titleOutcomes from the International Society of Nephrology Hemolytic Uremic Syndromes International Forumen
dc.typejournal article
degois.publication.firstPage1038
degois.publication.issue6
degois.publication.lastPage1050
degois.publication.titleKidney International
degois.publication.volume106
dspace.entity.typePublication
rcaap.rightsopenAccess

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
1-s2.0-S0085253824007051-main.pdf
Tamanho:
916.4 KB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

NMS - Artigos em revista internacional com arbitragem científica